N Acetyl cysteine
PreclinicalSmall molecule
N Acetyl cysteine is one of 15 small molecule programs targeting Acute Liver Failure. It is currently in Preclinical.
2
Indications
5
Total Trials
2
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Acute Liver Failure
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Medrol
PfizerPhase 2
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Benadryl
PParkedale
Phase 2
Equine Anti-Thymocyte Globulin
NNational Cancer Institute (NCI)
Phase 2
Plasma Exchange
SanofiPreclinical
Granulocyte Colony-Stimulating Factor
SanofiPreclinical
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Preclinical
Exosome
PParacrine Therapeutics Dermatology Pte. Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Beta-Thalassemia1 trial
Simethicone1 trial
Pre-medication With N-acetylcysteine and Simethicone to Improve Mucosal Visibility During Gastroduodenoscopy
Completed·—·N/A·NCT05951712·800 enrolled
Cerebral Infarction1 trial
Unspecified1 trial
The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels
Completed·—·Phase 1·NCT01251315·24 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for N Acetyl cysteine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TTanta University